OBJECTIVES: This study evaluated the validity of concerns about the toxicity of nevirapine (NVP) that have delayed its implementation as a perinatal HIV prevention strategy. METHODS: A decision analysis model compared 3 strategies: single-dose NVP, short-course zidovudine (ZDV), and no intervention. RESULTS: NVP would prevent more deaths than ZDV and no intervention as long as the rate of NVP toxicity did not exceed, respectively, 9 times that observed in the earlier NVP clinical trial and 42 times that observed in the clinical trial. NVP would be economically preferable to ZDV as long as the rate of toxicity did not exceed 22 times that observed in the clinical trial. CONCLUSIONS: Field implementation of NVP should not be delayed by concerns about its toxicity.
OBJECTIVES: This study evaluated the validity of concerns about the toxicity of nevirapine (NVP) that have delayed its implementation as a perinatal HIV prevention strategy. METHODS: A decision analysis model compared 3 strategies: single-dose NVP, short-course zidovudine (ZDV), and no intervention. RESULTS: NVP would prevent more deaths than ZDV and no intervention as long as the rate of NVP toxicity did not exceed, respectively, 9 times that observed in the earlier NVP clinical trial and 42 times that observed in the clinical trial. NVP would be economically preferable to ZDV as long as the rate of toxicity did not exceed 22 times that observed in the clinical trial. CONCLUSIONS: Field implementation of NVP should not be delayed by concerns about its toxicity.
Authors: F Dabis; P Msellati; N Meda; C Welffens-Ekra; B You; O Manigart; V Leroy; A Simonon; M Cartoux; P Combe; A Ouangré; R Ramon; O Ky-Zerbo; C Montcho; R Salamon; C Rouzioux; P Van de Perre; L Mandelbrot Journal: Lancet Date: 1999-03-06 Impact factor: 79.321
Authors: S Z Wiktor; E Ekpini; J M Karon; J Nkengasong; C Maurice; S T Severin; T H Roels; M K Kouassi; E M Lackritz; I M Coulibaly; A E Greenberg Journal: Lancet Date: 1999-03-06 Impact factor: 79.321
Authors: J B Jackson; G Becker-Pergola; L A Guay; P Musoke; M Mracna; M G Fowler; L M Mofenson; M Mirochnick; F Mmiro; S H Eshleman Journal: AIDS Date: 2000-07-28 Impact factor: 4.177
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: J S Stringer; D J Rouse; S H Vermund; R L Goldenberg; M Sinkala; A A Stinnett Journal: J Acquir Immune Defic Syndr Date: 2000-08-01 Impact factor: 3.731
Authors: M Culnane; M Fowler; S S Lee; G McSherry; M Brady; K O'Donnell; L Mofenson; S L Gortmaker; D E Shapiro; G Scott; E Jimenez; E C Moore; C Diaz; P M Flynn; B Cunningham; J Oleske Journal: JAMA Date: 1999-01-13 Impact factor: 56.272
Authors: Jeffrey S A Stringer; Moses Sinkala; Julia P Stout; Robert L Goldenberg; Edward P Acosta; Victoria Chapman; Rosemary Kumwenda-Phiri; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2003-04-15 Impact factor: 3.731
Authors: Elizabeth M Stringer; Moses Sinkala; Jeffrey S Stringer; Elizabeth Mzyece; Ida Makuka; Robert L Goldenberg; Pascal Kwape; Martha Chilufya; Sten H Vermund Journal: AIDS Date: 2003-06-13 Impact factor: 4.177